2024/03/25 更新

写真a

ナガヤマ ジュン
永山 洵
NAGAYAMA Jun
所属
医学部附属病院 泌尿器科 助教
職名
助教

学位 1

  1. 学士(医学) ( 2013年3月   三重大学 ) 

学歴 1

  1. 三重大学   医学部   医学科

    2007年4月 - 2013年3月

所属学協会 5

  1. 日本排尿機能学会

  2. 日本泌尿器腫瘍学会

  3. 日本泌尿器内視鏡・ロボティクス学会

  4. 日本癌治療学会

  5. 日本泌尿器科学会

受賞 1

  1. Young Oncologist Award

    2023年10月  

 

論文 4

  1. Efficacy of the Addition of Robot-assisted Radical Cystectomy with Extracorporeal Urinary Diversion after an Enhanced Recovery Protocol

    Nagayama J., Yamamoto A., Naito Y., Kamikawa H., Kanazawa H., Asano A., Sho N., Terashima Y.

    Urology journal   21 巻 ( 1 ) 頁: 40 - 46   2024年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Urology journal  

    PURPOSE: It is unclear if robotic radical cystectomy with extracorporeal urinary diversion (eRARC) provides additional benefit when performed along with enhanced recovery after surgery (ERAS). We assessed the additional efficacy of eRARC in terms of perioperative outcomes. MATERIALS AND METHODS: We retrospectively assessed 143 patients undergoing radical cystectomy with urinary diversion between June 2010 and December 2021 at a single center. The patients were assigned to three groups: open radical cystectomy (ORC) with conventional recovery after surgery (CRAS) [Group A], ORC with ERAS [Group B], and eRARC with ERAS [Group C]. A propensity score-matched analysis was performed to evaluate how ERAS and eRARC affected outcomes respectively. Meanwhile, multivariable analysis was used to detect the predictors of prolonged length of hospital stay (LOS). RESULTS: The median LOS was shorter after ERAS and eRARC. In the propensity score-matched analysis, ERAS was linked to a significantly shorter median LOS (28.0 vs. 20.0 days, P < .001), but eRARC was not associated with a shorter LOS (19.0 vs. 17.5 days, P = .21). Neither ERAS nor eRARC were connected with a reduce in complication rate. Following multivariable analysis, ERAS was found to be independently associated with shorter LOS (OR=0.23, P < .001), but eRARC demonstrated no such correlation (OR=0.29, P = .096). CONCLUSION: ERAS had strong association with shorter LOS, although eRARC did not contribute to additional efficacy. Neither ERAS nor eRARC decreased the complication rate.

    DOI: 10.22037/uj.v20i.7752

    Scopus

    PubMed

  2. Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate

    Naito, Y; Kato, M; Nagayama, J; Sano, Y; Matsuo, K; Inoue, S; Sano, T; Ishida, S; Matsukawa, Y; Tsuzuki, T; Akamatsu, S

    INTERNATIONAL JOURNAL OF UROLOGY   31 巻 ( 1 ) 頁: 7 - 16   2024年1月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Urology  

    Intraductal carcinoma of the prostate, a unique histopathologic entity that is often observed (especially in advanced prostate cancer), is characterized by the proliferation of malignant cells within normal acini or ducts surrounded by a basement membrane. Intraductal carcinoma of the prostate is almost invariably associated with an adjacent high-grade carcinoma and is occasionally observed as an isolated subtype. Intraductal carcinoma of the prostate has been demonstrated to be an independent poor prognostic factor for all stages of cancer, whether localized, de novo metastatic, or castration-resistant. It also has a characteristic genetic profile, including high genomic instability. Recognizing and differentiating it from other pathologies is therefore important in patient management, and morphological diagnostic criteria for intraductal carcinoma of the prostate have been established. This review summarizes and outlines the clinical and pathological features, differential diagnosis, molecular aspects, and management of intraductal carcinoma of the prostate, as described in previous studies. We also present a discussion and future perspectives regarding intraductal carcinoma of the prostate.

    DOI: 10.1111/iju.15299

    Web of Science

    Scopus

    PubMed

  3. Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy

    Tochigi, K; Nagayama, J; Bando, S; Ishiyama, A; Yuba, T; Yuguchi, Y; Matsui, H; Hattori, K; Gotoh, M

    INTERNATIONAL JOURNAL OF UROLOGY   29 巻 ( 11 ) 頁: 1264 - 1270   2022年11月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Urology  

    Objectives: Many studies have shown a good prognostic association with a large number of lymph node dissections. However, most of these studies did not include patients who have received neoadjuvant chemotherapy. The purpose of this study was to verify the relationship between survival outcomes and the number of lymph nodes removed during radical cystectomy in patients with muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy. Methods: This retrospective study considered patients who were diagnosed with clinical ≥T2N0M0 muscle-invasive bladder cancer and treated with radical cystectomy at the Nagoya University Hospital and affiliated hospitals from January 2004 to December 2019. We excluded patients who had a history of upper tract urothelial cancer or non-urothelial carcinoma. The association between prognosis and the number of lymph nodes removed was investigated. Results: We retrospectively enrolled a total of 477 patients. The mean number of lymph nodes dissected was 14. Two hundred and twenty-six patients (47.4%) received neoadjuvant chemotherapy. More extensive lymphadenectomy (≥15 lymph nodes) correlated with better 5-year overall survival across all patients (68% vs. 57%, p = 0.01). In patients who received neoadjuvant chemotherapy, there was no difference in overall survival according to the number of dissected lymph nodes (66% vs. 71%, p = 0.433). In patients who did not receive neoadjuvant chemotherapy, ≥15 lymph nodes dissected was associated with significantly better overall survival (70.3% vs. 46.9%, p < 0.01). Conclusions: No association between more aggressive lymph node dissection and prognosis was found in patients who underwent neoadjuvant chemotherapy. Conversely, extended lymph node dissection is desirable for patients who have not received neoadjuvant chemotherapy.

    DOI: 10.1111/iju.14974

    Web of Science

    Scopus

    PubMed

  4. Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer

    INOUE, S; SASSA, N; KAWANISHI, H; YUGUCHI, Y; SUZUKI, T; NAGAYAMA, J; MATSUI, H; MIYATA, Y; SOEDA, Y; TOCHIGI, K; YAMAUCHI, Y; MAEDA, M; KOBAYASHI, I; HATTORI, R; MATSUKAWA, Y; KATO, M

    ANTICANCER RESEARCH   42 巻 ( 7 ) 頁: 3627 - 3636   2022年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Anticancer Research  

    Background: The efficacy of anti-programmed cell-death protein 1 treatment in patients with urothelial carcinoma (UC) with molecular subtypes of histological variants has not been investigated. This study aimed to examine the impact of histological variants classified according to molecular subtypes on clinical outcomes in patients with platinum-resistant metastatic UC treated with pembrolizumab. Patients and Methods: Data of 168 patients with metastatic UC who received intravenous pembrolizumab after platinum-based chemotherapy between December 2017 and November 2020 were retrospectively reviewed. Relationships between histological variant type (basal or luminal molecular subtypes) and survival outcome and response to immunotherapy were examined. Clinicopathological factors were analyzed using the Cox proportional hazards model. Results: UC with histological variants was identified in 19 (11.3%) cases (basal subtype in 12; luminal subtype in 7). The median age of the patients was 72.5 years (range=40-89 years). The performance status was 0-1 in 151 (89.9%) patients. Liver metastasis was detected in 44 (26.2%) patients. The median progression-free survival was 3.5 months (range=0.5-34.3 months). Treatment with immune checkpoint inhibitors resulted in an overall mean survival (from the start of treatment) of 8.1 months (range=1.2-34.3 months). Patients with basal-type UC had significantly shorter progression-free survival and cancer-specific survival than those with pure UC (p=0.010 and p=0.035, respectively). A complete response was observed in eight patients (seven with pure UC, one with basal type). Conclusion: The basal histological variant might be a potential prognostic indicator in patients with platinum-resistant metastatic UC treated with pembrolizumab.

    DOI: 10.21873/anticanres.15851

    Web of Science

    Scopus

    PubMed

講演・口頭発表等 5

  1. 予後因子としてのエンホルツマブベドチン関連皮膚障害

    永山 洵

    第61回日本癌治療学会学術集会  2023年10月20日 

     詳細を見る

    会議種別:口頭発表(一般)  

  2. Panel Discussion: Case Management - Cytoreductive Nephrectomy 招待有り

    Jun Nagayama

    Advancements in Urology: An AUA/JUA Symposium (2024)  2024年3月7日 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  3.  エンホルツマブベドチンに起因する皮膚反応と初期治療効果の関連

    永山 洵

    第110回日本泌尿器科学会総会  2023年4月21日 

     詳細を見る

    会議種別:口頭発表(一般)  

  4. variant histologyを有する筋層浸潤膀胱癌に対する術前化学療法の有効性の検討

    永山 洵

    第110回日本泌尿器科学会総会  2023年4月22日 

     詳細を見る

    会議種別:口頭発表(一般)  

  5. 腹腔鏡下腎生検後の仮性動脈瘤破裂による大量出血に対して大量輸血および動脈塞栓術にて救命し得た一例

    永山 洵

    第294回日本泌尿器科学会東海地方会  2023年12月10日 

     詳細を見る

    会議種別:口頭発表(一般)